| For further information please contact |
| Peter Buhl Jensen, CEO |
| e-mail: pbj@medical-prognosis.com |
| Cell Phone: +45 21 60 89 22 |
Medical Prognosis Institute A/S - Interim Report First Half 2014
| Source: Allarity Therapeutics, Inc.
Recommended Reading
-
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion...
Read More -
Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environmentThe FDA requires that biomarker testing to select patients for registration...
Read More